Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hope Medicine kinase inhibitor (cancer cachexia)
- Development stage
- Preclinical
- Lead developer
- HopeMed
- Modality
- Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Fragment-Derived Small Molecules → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
Hope Medicine is developing an undisclosed kinase inhibitor, currently identified as Kinase Inhibitor (Program 1), for the treatment of cancer cachexia. Cancer cachexia is a complex metabolic syndrome characterized by the progressive loss of skeletal muscle mass and body weight in cancer patients, which significantly impacts quality of life and clinical outcomes. This program is part of Hope Medicine's early-stage pipeline, focusing on modulating kinase-mediated signaling pathways that contribute to muscle wasting or systemic inflammation associated with malignancy. While the specific molecular target and developmental stage have not been publicly disclosed, the program represents a targeted approach to addressing the unmet medical need in oncology-related metabolic dysfunction.
- Other names
- Kinase Inhibitor (Program 1)
Beyond the preview
Go deeper on Hope Medicine kinase inhibitor (cancer cachexia).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hope Medicine kinase inhibitor (cancer cachexia).